Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Chronic Pulmonary Hypertension Treatment Market Growth in 2025?
Over the past few years, the market for chronic pulmonary hypertension treatment has been expanding robustly. The projection indicates an enlargement from $6.82 billion in 2024 to $7.21 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. This significant historic growth is mainly due to factors such as the rising incidence of chronic pulmonary hypertension, an increase in the approval of drugs, beneficial reimbursement policies, escalating healthcare expenditure, and an aging population.
What Is the Forecast for the Chronic Pulmonary Hypertension Treatment Market Size Through 2029?
In the coming years, it is anticipated that the market size for chronic pulmonary hypertension treatment will experience robust growth. The market is projected to expand to a value of $8.95 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.6%. The predicted surge throughout this period is mainly due to the escalating demand for efficient treatments, magnified investments, a rise in government backing for drug invention, growing necessity for progressive therapeutics, enhanced awareness, and an increased occurrence of chronic brain injuries. The forecast period is also expected to see considerable trends such as new drug and therapy developments, technological improvements, collaborations with pharmaceutical corporations, research establishments, and healthcare institutions, discovery of new molecular pathways, investments from governments and healthcare bodies, and innovation of fresh therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21148&type=smp
What are the Key Market Players in Chronic Pulmonary Hypertension Treatment Market and How They’re Evolving?
Major companies operating in the chronic pulmonary hypertension treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi SA, AstraZeneca PLC, Novartis AG, GSK (GlaxoSmithKline), Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Insmed, Cereno Scientific, Roivant Sciences, LGM Pharma, Liquidia Technologies
What Are the Primary Growth Drivers in the Chronic Pulmonary Hypertension Treatment Market?
The chronic pulmonary hypertension treatment market’s growth is expected to be driven by the high prevalence of cardiovascular diseases. These diseases, which include conditions such as coronary artery disease, stroke, and heart failure, correspond to various illnesses affecting the heart and blood vessels. Factors contributing to the high prevalence of cardiovascular diseases include unhealthy eating habits, lack of physical activity, tobacco usage, excessive drinking, obesity, high blood pressure, diabetes, and an aging population. By reducing pulmonary artery pressure, improving heart function, and minimising the risk of heart failure and its associated complications, chronic pulmonary hypertension treatment contributes to cardiovascular wellbeing. For example, as reported by the Australian Institute of Health and Welfare, a governmental agency in Australia, in December 2023, there were 14,100 deaths confirmed by doctors due to coronary heart disease (CHD) in 2021, which escalated to 14,900 in 2022. Consequently, the growth of the chronic pulmonary hypertension treatment market is spurred by the high prevalence of cardiovascular diseases.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21148&type=smp
What Are the Leading Segments in the Global Chronic Pulmonary Hypertension Treatment Industry?
The chronic pulmonary hypertension treatment market covered in this report is segmented –
1) By Drug Type: Endothelin Receptor Antagonists, Phosphodiesterase (PDE-5) Inhibitors, Prostacyclin Analogs, Soluble Guanylate Cyclase (SGC) Stimulators
2) By Route Of Administration: Oral, Intravenous Or Subcutaneous, Inhalational
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Endothelin Receptor Antagonists: Bosentan, Ambrisentan, Macitentan
2) By Phosphodiesterase (PDE-5) Inhibitors: Sildenafil, Tadalafil, Vardenafil
3) By Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost
4) By Soluble Guanylate Cyclase (SGC) Stimulators: Riociguat
What Are the Key Market Trends in the Chronic Pulmonary Hypertension Treatment Industry?
Major firms within the chronic pulmonary hypertension therapy business are concentrating their efforts on creating innovative solutions like subcutaneous injections which aim to advance patient conformity, offer more specialized treatment options, and promote convenience. By delivering continuous medication under the patient’s skin, subcutaneous injections help decrease the pulmonary artery pressure and enhance pulmonary hypertension patients’ blood flow. For example, Merck & Co Inc., a pharmaceutical company based in the US, stated in March 2024 that Winrevair (sotatercept-csrk) had received approval from the U.S. Food and Drug Administration (FDA). This marks a notable progress in pulmonary arterial hypertension (PAH) therapy. The breakthrough therapy segregates itself through its unique benefits. Clinical trials displayed an improvement in the WHO functional class in 29% of patients, a significant increase compared to the 14% in the placebo group, thus greatly improving their quality of life.
Access The Full Report Here:
What Is the Regional Outlook for the Chronic Pulmonary Hypertension Treatment Market?
North America was the largest region in the chronic pulmonary hypertension treatment market in 2024. The regions covered in the chronic pulmonary hypertension treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21148
This Report Delivers Insight On:
1. How big is the chronic pulmonary hypertension treatment market, and how is it changing globally?
2. Who are the major companies in the chronic pulmonary hypertension treatment market, and how are they performing?
3. What are the key opportunities and risks in the chronic pulmonary hypertension treatment market right now?
4. Which products or customer segments are growing the most in the chronic pulmonary hypertension treatment market?
5. What factors are helping or slowing down the growth of the chronic pulmonary hypertension treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model